We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Outlines Combination Contraceptive Labeling in New Draft Guidance
FDA Outlines Combination Contraceptive Labeling in New Draft Guidance
A new FDA draft guidance recommends sponsors include new class labeling and prescribing information for combined hormonal contraceptives containing estrogen and progestin.